Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 15;12(4):E545–E553. doi: 10.1055/a-2280-8277

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.

PMC Copyright notice

Fig. 4 — Line graph showing the annual chronological change in the total EREFS from the first diagnosis to the last follow-up. The number of patients who underwent endoscopy at each follow-up period is shown at the bottom of the figure. The horizontal short dotted line represents the median value of the total EREFS at each follow-up period. EREFS, EoE endoscopic reference score; m, month; pts, patients; Dx, diagnosis; PPI, proton pump inhibitor; PCAB, potassium competitive acid blocker; aEE, asymptomatic esophageal eosinophilia; mEoE, minimally symptomatic EoE. a Tx-diffuse group, which includes patients with diffuse-type EoE who continuously received PPI/PCAB. a, P = 0.0313; b, P = 0.0078 (vs. at the first diagnosis). b Tx-localized group, which consists of patients with localized-type EoE who continuously received PPI/PCAB. c NT-diffuse group, which consists of patients with diffuse-type aEE or mEoE who were continuously untreated. d NT-localized group, which consisted of patients with localized-type aEE or mEoE who are continuously untreated. a, P =0.0313; b, P =0.0034; c, P =0.0137; d, P =0.0039; e, P =0.0010 (vs. at the first diagnosis).